BB Biotech Q2 2026: Robust NAV Performance Amid Strategic Investments

BB Biotech delivered a notable performance in Q2 2026, achieving a NAV return of +17.2% in CHF and EUR, and +15.9% in USD, surpassing the Nasdaq Biotechnology Index by 3.5 percentage points. The company reported a net profit of CHF 451 million, reversing a net loss in the same quarter last year. Twelve new investments were initiated, expanding the portfolio to 39 positions, reflecting enhanced research capabilities.

Portfolio activity included acquisitions, with three M&A transactions announced in 2026, underscoring the strategic value of innovation in biotechnology. The introduction of a target dividend yield of 3-5% aligns shareholder distributions with long-term performance.

Despite macroeconomic challenges and capital market fluctuations, BB Biotech's portfolio benefitted from strong clinical developments and strategic M&A activities. The company maintains a forward-looking outlook, leveraging a diversified portfolio and advanced AI-enabled investment processes for future growth.